Research
Hormonal
Exercise reduces levels of detrimental hepatokines like Fetuin A and Selenoprotein P, which contributes to decreased visceral adipose tissue (VAT) mass and improved insulin sensitivity.
Regular aerobic exercise helps lower levels of Fetuin A, a liver hormone linked to fat storage and insulin resistance. By reducing this hormone, exercise helps your body manage fat better and improves insulin sensitivity, contributing to overall fat loss.
ModerateSupportsMEDIUM confidence
Concordantly, increasing levels of fetuin A were associated with increasing VAT mass... a recent meta-analysis found decreased fetuin A levels following completion of aerobic exercise regimes... leading to decreased hepatic insulin resistance, total body fat, and fasting insulin levels.
Why this rating
Based on meta-analyses and clinical studies cited in the review.
Source
The Role of Exercise in the Interplay between Myokines, Hepatokines, Osteokines, Adipokines, and Modulation of Inflammation for Energy Substrate Redistribution and Fat Mass Loss: A Review
Adrian M. González-Gil et al. · Nutrients · 2020
DOI 10.3390/nu12061899
narrative_reviewCited 261×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Exercise induces the release of myokines (irisin, IL-6, IL-15, METRNL, BAIBA) and hepatokines (FGF21, ANGPTL4, follistatin) which mediate fat mass loss by promoting white adipose tissue (WAT) browning, increasing fatty acid oxidation, and reducing systemic inflammation.Moderate
- High baseline levels of the hepatokine Selenoprotein P (SeP) are associated with 'exercise resistance,' blunting the beneficial metabolic adaptations to exercise and reducing aerobic capacity in obese individuals.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →